As our sub-group comparisons, as well as DTECT mapping using both TTF1 and cMYC expression, had all indicated that Aurora Kinase inhibition was more effective in cMYC high SCLC cell lines, we performed a supervised analysis of candidate proteomic biomarkers of response to single agent alisertib in a panel of 51 SCLC cell lines [31]. This evidence concerns the gene TTF1 and small cell lung carcinoma.